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Abstract
 
The insulin gene transcription factor PDX-1/IPF1/STF-1/
IDX-1 plays a key role in directing 
 
b
 
 cell–specific gene ex-
pressions. Recently, impairment of PDX-1 expression or ac-
tivity has been observed in 
 
b
 
 cell–derived HIT cells cultured
under high glucose concentrations, and this has been sug-
gested as a possible cause of the decrease in insulin gene
transcription. To investigate the pathophysiological signifi-
cance of PDX-1 as a determinant of the rate of insulin gene
transcription, we suppressed its expression in 
 
b
 
 cell–derived
MIN6 cells using an antisense oligodeoxynucleotide (ODN)
and searched for possible changes in the 
 
b
 
 cell–specific gene
expression. Treatment of MIN6 cells with an 18-mer phos-
phorothioate ODN complementary to a sequence starting at
the translation initiation codon of PDX-1 caused a potent,
concentration-dependent reduction in PDX-1 expression;
addition of 2 
 
m
 
M antisense ODN could reduce PDX-1 ex-
pression to 14
 
6
 
4% of the control. There was also a decrease
in its DNA binding to the insulin gene A element. Despite
such suppression of PDX-1, Northern blot analysis revealed
no decrease in the amount of insulin mRNA in the MIN6
cells. Similarly, no changes were detected in the transcrip-
tion of the glucokinase or islet amyloid polypeptide gene,
for which PDX-1 was shown to function as a transcription
factor. Thus, our findings dispute the physiological signifi-
cance of PDX-1 in determining the rate of insulin gene tran-
scription. This means that other components constituting
the transcription-controlling machinery need to be evalu-
ated in order to understand the molecular basis of impaired
insulin biosynthesis such as that observed due to glucose
toxicity. (
 
J. Clin. Invest.
 
 1997. 100:1840–1846.) Key words:
gene expression regulation 
 
• 
 
transcription factors 
 
• 
 
homeo-
domain protein 
 
• 
 
antisense oligodeoxynucleotide
 
Introduction
 
Non–insulin-dependent diabetes mellitus (NIDDM)
 
1
 
 is a mul-
tifactorial disease characterized by insulin resistance and im-
paired insulin secretion (1). Characterization of NIDDM
model animals has revealed extensive degranulation of pan-
creatic 
 
b
 
 cells that can be observed simultaneously with the on-
set of overt diabetes, thus suggesting the significance of the im-
pairment of insulin synthesis as a cause of disturbed 
 
b
 
 cell
function (2, 3). To understand the molecular background for
such a decrease in insulin synthesis, we need to identify the
molecular components that determine the rate of insulin gene
transcription and how their function is disturbed in NIDDM
cases.
Among various factors that potentially inhibit insulin bio-
synthesis, glucose toxicity has been the main focus of recent re-
search. Prolonged exposure of pancreatic 
 
b
 
 cells to high glu-
cose levels exerts toxic effects on the cells (glucose toxicity),
which can be characterized by impaired insulin biosynthesis
and extensive degranulation (4). Recently, the pancreatic 
 
b
 
cell–derived HIT cell has been used as a model to show that
exposure of the cells to chronic high glucose concentration (5–7)
or to 
 
D
 
-ribose (8), which induces a glycation reaction, causes
reduction of insulin gene promoter activity and, subsequently,
decreases in insulin mRNA and insulin content. These studies
also revealed a reduction in the DNA-binding activity of the 
 
b
 
cell–specific transactivating factor PDX-1/IPF1/STF1/IDX-1
(9–11). Thus, the possibility arose that the impaired PDX-1
function per se is pathophysiologically responsible for the de-
crease in insulin gene promoter activities. A similar reduction
in PDX-1 expression was observed in pancreatic 
 
b
 
 cells in vivo;
in 90% pancreatectomized diabetic rats, chronic hyperglyce-
mia was associated with decreased mRNA levels of both insu-
lin and PDX-1 (12).
PDX-1 is a homeodomain-containing transcription factor
which binds to the A element motif of the insulin genes and
contributes to directing the genes’ 
 
b
 
 cell–specific expression
(9). Among the various transcription factors of the insulin
gene, including those yet to be cloned, such as RIPE3b1 (13),
the physiological significance is most evident for PDX-1 (14,
15). The transcription factor appears before insulin during the
ontogeny of the mouse pancreas, and its expression eventually
becomes restricted to the 
 
b
 
 cells in the adult (15). Besides its
role in insulin gene expression, PDX-1 has been suggested to
be involved in glucokinase and islet amyloid polypeptide
(IAPP) gene expressions (16–18).
As a step toward elucidating the machinery that deter-
mines the rate of insulin gene transcription and understanding
the molecular basis of the impaired insulin biosynthesis ob-
served in NIDDM patients, we investigated the role of PDX-1
in determining the transcriptional rate of insulin and other 
 
b
 
cell–specific genes. To suppress PDX-1 expression in 
 
b
 
 cell–
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derived MIN6 (19) and 
 
b
 
TC1 (20) cells, we used an antisense
oligodeoxynucleotide (ODN) strategy and then evaluated the
effects on gene expression. We report here that, unlike sup-
pression of another insulin gene transcription factor, E2A/Pan
(21), which constitutes E element–binding IEF1 (13), suppres-
sion of PDX-1 expression causes no changes in insulin gene ex-
pression.
 
Methods
 
Materials.
 
Radioisotopes were purchased from Amersham Japan
(Tokyo, Japan). Tissue culture media were purchased from Nacalai
Tesque, Inc. (Kyoto, Japan), and FBS was from ICN Biomedicals,
Inc. (Costa Mesa, CA). The anti–PDX-1 (IPF1) antiserum was estab-
lished recently by us (16) after immunizing a rabbit with the synthetic
peptide SPQPSSIAPLRPQE representing amino acid residues 269–
282 of the PDX-1 peptide (GenBank accession number X74342) (9).
The anti-NeuroD polyclonal antibody (sc-1084) was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Basic laboratory
procedures were performed according to standard protocols (22) un-
less otherwise stated.
 
ODNs.
 
An 18-mer phosphorothioate antisense ODN comple-
mentary to a sequence starting at the ATG initiation codon of mouse
PDX-1 (5
 
9
 
-CTGCTCCTCACTGTTCAT-3
 
9
 
) and control sense and
reverse phosphorothioate ODNs (5
 
9
 
-ATGAACAGTGAGGAG-
CAG-3
 
9
 
 and 5
 
9
 
-TACTTGTCACTCCTCGTC-3
 
9
 
, respectively) were
synthesized using an automated DNA synthesizer (model 391; Ap-
plied Biosystems, Foster City, CA).
 
Cell culture and ODN treatment of cells.
 
b
 
 Cell–derived cell line
MIN6 cells (19) were grown in DME supplemented with 15% heat-
inactivated FBS, penicillin, and streptomycin. 
 
b
 
 Cell–derived cell line
 
b
 
TC1 (20) and HIT-T15 cells (1777; American Type Culture Collec-
tion, Rockville, MD) were grown in RPMI 1640 supplemented with
10% heat-inactivated FBS, penicillin, and streptomycin. For ODN
treatment, MIN6 and 
 
b
 
TC1 cells (
 
z
 
 80% confluent in 60-mm dishes)
were washed twice with 6 ml DME (for MIN6) or RPMI 1640 (for
 
b
 
TC1) containing no serum. Appropriately diluted aliquots of ODN
in 288 
 
m
 
l DME or RPMI 1640 (no serum) were preincubated at room
temperature for 15 min with 288 
 
m
 
l DME or RPMI 1640 (no serum)
containing 26 
 
m
 
l of LipofectAMINE
 
®
 
 reagent (Life Technologies,
Inc., Gaithersburg, MD). This mixture was added to the cells together
with an additional 2.3 ml of DME or RPMI 1640 (no serum). The fi-
nal concentrations of ODN were as indicated. Cells were incubated
for 5 h at 37
 
8
 
C in the presence of 5% CO
 
2
 
. Next, the serum-free me-
dium containing LipofectAMINE was removed, and the incubation
was continued with fresh (serum-containing) medium which also in-
cluded appropriate concentrations of ODN. The medium was re-
placed every 48 h with fresh medium of the same content.
 
Western blot analysis.
 
Nuclear extracts were prepared following
the procedure described by Sadowski and Gilman (23). 3 
 
m
 
g of nu-
clear extract was separated by SDS-PAGE (10% resolving gel) using
a Minigel
 
®
 
 apparatus (Bio-Rad Laboratories, Hercules, CA), and
transferred to polyvinylidene fluoride membranes (Immobilon-P; Ni-
hon Millipore, Tokyo, Japan) using transfer buffer containing 20%
methanol, 25 mM Tris base, and 192 mM glycine and a Mini-trans-
electrophoretic transfer cell (Bio-Rad Laboratories) (100 V, 1 h). Af-
ter blocking the membranes for 1–2 h at room temperature in PBS
containing 3% BSA, the membranes were incubated at room temper-
ature for 60 min in TBS buffer (20 mM Tris-HCl, 150 mM NaCl, pH
7.5) containing 1:5,000 dilution of anti–PDX-1 (IPF1) antiserum (16)
or anti-NeuroD polyclonal antibody, and washed three times (10 min
each time) in TBS with 0.2% Tween-20 (TBS-T). The membranes
were then incubated for 60 min at room temperature in TBS contain-
ing 1:5,000 dilution of goat anti–rabbit IgG antibody (for PDX-1 de-
tection) or porcine anti–goat IgG antibody (for NeuroD detection)
coupled to horseradish peroxidase, followed by two 30-min washings
with TBS-T. Immunoreactive bands were visualized by incubation
with luminol (ECL
 
®
 
 Western Blotting Kit; Amersham Japan) and ex-
posed to XAR-5 film (Eastman Kodak Co., Rochester, NY). Quanti-
fication was achieved by densitometric scanning.
 
Gel mobility–shift analysis.
 
3 
 
m
 
g of nuclear extract was preincu-
bated with 2 
 
m
 
g of poly(dI-dC) at 4
 
8
 
C in a 20-
 
m
 
l reaction mixture con-
taining 20 mM Hepes, pH 7.9, 75 mM KCl, 2.5 mM MgCl
 
2
 
, 1 mM
DTT, 1 mM EDTA, and 3% Ficoll-Hypaque (vol/vol%). 15 min
later, the binding reaction was initiated by adding 100 pg (10
 
4
 
 cpm) of
5
 
9
 
-end 
 
32
 
P-labeled ODN probes and, when required, nonradioactive
competitor double-stranded ODNs, followed by incubation at room
temperature for 30 min. In some of the binding assays, 2 
 
m
 
l of preim-
mune serum or anti–PDX-1 antiserum was added to the binding reac-
tions 30 min before addition of the DNA probes. The samples were
fractionated on 5% PAGE precooled to 4
 
8
 
C in 0.5
 
3
 
 TBE (45 mM
Tris base, 45 mM boric acid, 1 mM EDTA). Quantification was
achieved by densitometric scanning after exposure to Kodak XAR-5
film.
 
Northern blot analysis.
 
Northern blots followed standard proce-
dures using 25 
 
m
 
g of total RNA isolated from MIN6 cells or 10 
 
m
 
g of
total RNA isolated from 
 
b
 
TC1 or HIT-T15 cells. A mouse glucoki-
nase cDNA (nucleotides 152–725) (24) and a mouse IAPP cDNA
(nucleotides 
 
2
 
4–245) (25) were prepared by reverse transcription–
PCR using MIN6 total RNA as a template and subcloned individually
into the pBluescript II plasmid. The mouse PDX-1 cDNA had been
generated by us previously (18). The plasmid pMIn2C containing a
mouse insulin II cDNA was a generous gift from Drs. J.M. Chirgwin
Figure 1. Effect of antisense ODN on suppression of PDX-1 expres-
sion in MIN6 cells. Western blot analysis using anti–PDX-1 antiserum 
(top) and anti-NeuroD antibody (bottom). MIN6 cells were exposed 
to 1 or 2 mM antisense or 2 mM sense ODN for 48 h. LipofectAMINE 
was used for the initial transfection of ODNs, and thereafter, ODNs 
alone were added. 3 mg each of the same nuclear extracts prepared 
from MIN6 cells was used for evaluation of PDX-1 and NeuroD ex-
pression.
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(University of Texas Health Science Center) and M.A. Permutt
(Washington University School of Medicine).
 
Results
 
Suppression of PDX-1 expression by antisense ODN.
 
Using the
antisense ODN strategy, we suppressed the expression of
PDX-1 in the pancreatic 
 
b
 
 cell–derived MIN6 cells (19). A set
of antisense, sense, and reverse ODNs was designed to include
the 18-nucleotide coding sequences starting with the first me-
thionine codon of the PDX-1 mRNA. To investigate whether
the antisense ODN can efficiently suppress the expression of
PDX-1, Western blotting analyses were performed using nu-
clear extracts which were isolated after incubation with the
ODN for 48 h. As shown in Fig. 1, the antisense ODN could
substantially suppress PDX-1 expression. The expression of
another insulin gene transcription factor, NeuroD, examined
as a control, was not affected (Fig. 1). We also examined the
amount of PDX-1 mRNA by Northern blot analysis, but found
no decrease by the antisense ODN (data not shown). This may
indicate that the antisense ODN used in this study functioned via
a hybrid-arrested translation rather than via RNase H–driven
mRNA cleavage as suggested in the literature (21, 26).
Results of more detailed analyses of antisense PDX-1 ef-
fects are shown in Figs. 2–4. In terms of the effects of different
concentrations of the antisense ODNs, representative results
are shown in Fig. 2 
 
A
 
, and average data are shown as a graph
in Fig. 2 
 
B.
 
 The substantial suppression of PDX-1 expression
was observed in MIN6 cells when kept for 48 h in the presence
of a supramicromolar concentration of antisense ODN [down
to 14
 
6
 
4% (mean
 
6
 
SE) under 2 
 
m
 
M antisense ODN]. No fur-
ther decrease was observed even when concentrations 
 
.
 
 2 
 
m
 
M
were used (Fig. 2, 
 
A
 
 and 
 
B
 
, lanes 
 
8–10
 
). In contrast to the sup-
pressive effect of antisense ODN, no effect was observed after
addition of 2 
 
m
 
M sense or reverse ODN (Fig. 2 
 
A
 
, lanes 
 
11
 
, 
 
13
 
,
Figure 2. Concentration-dependent suppression of PDX-1 expression 
in MIN6 cells due to antisense ODN exposure. (A) Western blot analy-
sis using anti–PDX-1 antiserum. MIN6 cells were exposed to antisense, 
sense, or reverse ODN at the concentrations indicated below for 48 h. 
LipofectAMINE was used for the initial transfection of ODNs, and 
thereafter, ODNs alone were added. 3 mg of nuclear extracts prepared 
from MIN6 cells was used. (B) PDX-1 expression in MIN6 cells ex-
posed to antisense (filled circles), sense (open square), and reverse 
(closed square) ODN at various concentrations for 48 h. The band in-
tensity was measured using laser scanning densitometry. The amount 
observed without ODN (LipofectAMINE only) was set arbitrarily at 
100%. The results are shown as the means6SE of at least three inde-
pendent experiments.
Figure 3. Time course of suppression of PDX-1 expression by anti-
sense ODN. MIN6 cells were incubated with or without 2 mM anti-
sense ODN for 24, 48, or 144 h. LipofectAMINE was used for the ini-
tial transfection, and ODNs alone were added thereafter. 3 mg of 
nuclear extracts prepared from MIN6 cells were used for Western 
blot analysis. Similar results were obtained in three independent ex-
periments.
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and 
 
14, 
 
and 
 
B
 
). Also, the gene transferring agent Lipo-
fectAMINE itself did not affect the expression level of PDX-1
(Fig. 2 
 
A
 
, lanes 
 
6
 
 and 
 
7
 
).
The time course of the PDX-1 suppression after addition of
antisense ODN to MIN6 cells was examined. As shown in Fig.
3, exposure of MIN6 cells to 2 
 
m
 
M antisense ODN caused a
rapid decrease in PDX-1 expression within 24 h, and the sup-
pressive effects continued until at least 144 h after the initial
addition of antisense ODN. Considering the half-life of insulin
mRNA, which is 6–12 h according to results obtained previ-
ously with 
 
b
 
 cell–derived RIN-5F and 
 
b
 
TC6 cells (27, 28), this
time course of suppression by 2 
 
m
 
M antisense ODN was suit-
able for evaluating the effects of PDX-1 diminution on insulin
mRNA amounts. Thus, we used MIN6 cells that had been kept
with antisense ODN for 96 h to evaluate the potential role of
PDX-1 in determining the rate of insulin gene transcription.
 
Suppression of PDX-1 binding to A element by antisense
ODN.
 
To examine whether the antisense ODN–dependent
reduction of PDX-1 expression in MIN6 cells would lead to a
decrease in its binding to the 
 
cis
 
-acting motifs, we performed
gel mobility–shift analyses using the human insulin gene A3 el-
ement (hInsA3) as a probe. The results revealed that, in accor-
dance with the reduction of the amount of PDX-1 protein ob-
served by Western blot analysis (Fig. 4 
 
A
 
), the intensity of the
band formed with the hInsA3 probe and a nuclear protein in
MIN6 cells was reduced in a dose-dependent manner by addi-
tion of antisense ODN (Fig. 4 
 
B
 
). The average band intensities
in gel mobility–shift analyses for 1 and 2 
 
m
 
M antisense and 2
 
m
 
M sense ODN lanes were 28
 
6
 
5, 18
 
6
 
5, and 80
 
6
 
7%, respec-
tively, of that for the control lane. The gel–shift complex was
shown to include PDX-1, because the addition of anti–PDX-1
(IPF1) antiserum to the binding reaction caused diminution in
band intensity (Fig. 4 
 
C
 
). These results indicated that the re-
duction in the protein amount of PDX-1 by antisense ODN
caused a comparable reduction in its DNA-binding capacity.
 
Effect of PDX-1 reduction on insulin, glucokinase, and
IAPP mRNA amounts.
 
We examined whether the decrease in
PDX-1 protein and DNA-binding capacity would reduce the
expression of insulin gene or other potential target genes. As
shown in Fig. 5, the amount of insulin mRNA did not change
in cells in which PDX-1 expression was suppressed. When the
band intensity for the control lane was arbitrarily set at 100%,
the average intensities for 1 and 2 
 
m
 
M antisense and 2 
 
m
 
M
sense ODN lanes were 82
 
6
 
9, 94
 
6
 
13, and 113
 
6
 
22%, respec-
tively (n 5 3; representative data shown in Fig. 5). Similarly,
no changes were observed in the amount of glucokinase
(10466, 114611, and 119616%, n 5 3; Fig. 5) or IAPP mRNA
(10167, 112610, and 121614%, n 5 3; Fig. 5). Thus, these ob-
servations suggest that suppression of PDX-1 expression does
not affect the transcriptional rate of these genes.
Suppression of PDX-1 and expression of insulin gene in
bTC1 cells. To investigate whether similar observations would
be obtained with some other immortalized b cell–derived
lines, we suppressed the PDX-1 expression in bTC1 cells and
investigated the expression of insulin mRNA. With the same
methods and ODNs used for MIN6 cells, the expression of
PDX-1 was suppressed substantially in bTC1 cells (Fig. 6;
down to 2464% with 2 mM antisense ODN, n 5 3). Despite
Figure 4. Inhibition of binding of PDX-1 
to A element by antisense ODN. (A) 
Western blot analysis using anti–PDX-1 
antiserum. MIN6 cells were exposed to 1 
or 2 mM antisense or 2 mM sense ODN for 
96 h. 3 mg of nuclear extracts prepared 
from MIN6 cells were used for Western 
blot analysis. The same nuclear extracts 
were used for gel mobility–shift analysis, 
shown in B. (B) Evaluation of A element–
binding activity by gel mobility–shift
analysis. The binding probe was a double-
strand ODN reproducing the hInsA3
region and surrounding sequences
(59-CCCCTGGTTAAGACTCTAAT-
GACCCGCTGG-39). (C) Identification of 
the binding protein by gel mobility–shift 
analysis. Using wild-type and mutated-
type (59-CCCCTGGTTAAGACTCTccT-
GACCCGCTGG-39) competitors and 
preimmune and antiserum against PDX-1 
as indicated, the specificity and identity of 
the gel–shift complex were evaluated. The 
nuclear extracts used were isolated from 
untreated MIN6 cells. B and C were parts 
of the same gel, and the mobilities of the 
complexes were identical.
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this, no changes in the insulin mRNA amount were observed
(control, arbitrarily set at 100%; 1 mM antisense, 10964%; 2
mM antisense, 121614%; 2 mM sense, 9667%; n 5 3).
Comparison of PDX-1 expression with that in HIT-T15
cells chronically exposed to high glucose conditions. Suppres-
sion of PDX-1 expression was coidentified with the suppres-
sion of insulin gene expression in HIT cells which had been ex-
posed to high glucose concentration for a very long period (7,
29), and therefore was suggested to be responsible for the de-
crease in insulin gene expression. To allow comparison of our
results with this observation in HIT-T15 cells, we examined
whether the degree of decrease in PDX-1 in our study was
comparable to that observed in the chronic high glucose–
exposed HIT cells.
As shown in Fig. 7, the HIT-T15 cells of a late passage
number (P98) showed substantial decrease in insulin mRNA
content (down to 5065% of the control [P70]; n 5 3). The
PDX-1 amount in the cells may also have decreased slightly
(down to 78612% of the control [P70]; n 5 3); however, the
degree of decrease in PDX-1 was definitely greater in our anti-
sense ODN–treated MIN6 cells than in the HIT-T15 cells ex-
periencing impaired insulin biosynthesis due to chronic high
glucose condition. This disputes the idea that the suppression
of PDX-1 is primarily responsible for the impaired insulin bio-
synthesis in such HIT-T15 cells.
Discussion
Loss of PDX-1 results in loss of the pancreas, showing that
PDX-1 has an important physiological role in the development
of this organ (14, 15). Recently, Serup et al. and we ourselves
reported that PDX-1 can contribute to the expression of a sub-
set of b cell–specific genes when exogenously expressed in cell
lines derived from pancreatic a cells (18, 30). Thus, the pres-
ence of PDX-1 is clearly important in directing the expression
of b cell–specific genes. However, whereas multiple transcrip-
tion factors are known to be involved in insulin or glucokinase
gene expression, the physiological significance of PDX-1 as a
determinant of the transcriptional rate of those genes has re-
mained unknown.
In this study, we succeeded in substantially reducing PDX-1
expression in MIN6 cells using the antisense ODN strategy
(Figs. 1–3 and 6). The reduction in protein amount also caused
diminution of PDX-1 binding to the target DNA (Fig. 4). Nev-
ertheless, we found no changes in the expression of insulin or
other b cell–specific genes. Also, this seemed conserved in an-
other b cell–derived cell line, bTC1. Although these findings
dispute the physiological significance of PDX-1 in determining
the rate of insulin gene transcription, they do not completely
deny its involvement in driving insulin gene expression in b
cells. We assume it is possible that PDX-1 may be a sufficiently
abundant protein in b cell–derived cells such that diminishing
its expression levels by 80–90% does not impede its overall
function as a transcription factor. In this case, as long as the
minimally required amount of PDX-1 is expressed in the cells,
no remarkable changes in gene expression would occur in the
PDX-1–suppressed b cell–derived cells. Thus, we consider it
safe to conclude that the moderate suppression of PDX-1 ex-
Figure 5. Absence of reduction of insulin, glucokinase, or IAPP gene 
expression in PDX-1–suppressed MIN6 cells. Northern blot analyses 
were used to evaluate a subset of b cell–specific gene expression. The 
binding probe was 32P-labeled glucokinase, IAPP, or insulin cDNA. 
25 mg of total RNA was isolated from MIN6 cells which had been ex-
posed for 96 h to LipofectAMINE alone (lane 1), 1 mM antisense 
(lane 2), 2 mM antisense (lane 3), and 2 mM sense ODN (lane 4). Bot-
tom, Ribosomal RNA.
Figure 6. Absence of reduction of insulin gene expression in PDX-1–
suppressed bTC1 cells. bTC1 cells were exposed to 1 or 2 mM anti-
sense or 2 mM sense ODN for 96 h. LipofectAMINE was used for the 
initial transfection of ODNs, and thereafter, ODNs alone were 
added. Top, Result of Northern blot analysis which used anti–PDX-1 
antiserum and 3 mg of nuclear extracts. Middle, Result of Northern 
blot analysis which used 10 mg of total RNA and a 32P-labeled insulin 
cDNA as a binding probe. Nuclear extracts and total RNA were iso-
lated from MIN6 cells which had been exposed for 96 h to Lipo-
fectAMINE alone (lane 1), 1 mM antisense (lane 2), 2 mM antisense 
(lane 3), and 2 mM sense ODN (lane 4). Bottom, Ribosomal RNA.
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pression such as that achieved in this study is not likely to af-
fect the gene expression pattern in the cells.
Our observation provides useful information for the under-
standing of b cell glucose toxicity. To date, a decrease of PDX-1
protein or its binding to the target DNA has been coidentified
with a decrease in insulin biosynthesis in HIT cells kept under
chronic high glucose condition (7, 29) or with D-ribose, which
induces a glycation reaction (8). Therefore, PDX-1 has been
suggested to be responsible for the decrease in insulin gene
transcription due to glucose toxicity. Although the cell lines
used were not the same, the degree of reduction in PDX-1 ex-
pression in our antisense ODN–treated cells was greater than
that observed in the HIT-T15 cells of passage 98 (P98), which
had reduced insulin gene expression caused by chronic high
glucose condition (Figs. 1–3 and 7). We would like to note that
Moran et al. seem to have found a similar phenomenon re-
cently using HIT-T15 cells of the same age (31). Thus, our re-
sults suggest that the reduction of PDX-1 is not a primary
cause for the decrease in insulin gene transcription in HIT-T15
cells.
In contrast to these observations on PDX-1–suppressed
b cells, the suppression of another insulin gene transcription
factor, E2A/Pan, in b cell–derived RIN cells caused dramatic
attenuation of insulin gene transcription (21). E2A (E47/E12)/
Pan (Pan-1/Pan-2) are ubiquitously expressed basic helix-loop-
helix proteins which constitute a heterodimer, called IEF1,
with the recently described tissue-specifically expressed basic
helix-loop-helix protein, BETA2/NeuroD (32, 33). The het-
erodimer IEF1 binds to an important cis-motif of the insulin
gene promoter E element (IEB/Nir, Far) (13), and activates
transcription. Although both IEF1-binding E elements and
PDX-1–binding A elements play a major role in the b cell–spe-
cific expression of the insulin gene (34, 35), their physiological
roles may differ in terms of their commitment to the rate of
transcription. We assume that this difference may be related to
the fact that PDX-1 is a homeodomain-containing protein.
Usually, the physiological function of a homeodomain-con-
taining transcription factor is exerted by switching its expres-
sion on and off; whether it is completely absent or present in a
cell is important, for example, in the determination of cell fate
(36, 37). Although speculative, this may also be the case with
PDX-1; the existence of only a small amount of PDX-1 may be
essential and adequate for acquiring the b cell trait in terms of
the gene expression pattern. In this regard, the PDX-1 amount
may be of little physiological significance as long as it is above
a certain critical level.
If PDX-1 is not primarily responsible for the decrease in in-
sulin gene transcription due to glucose toxicity, what is the re-
sponsible factor? Although E2A/Pan suppression has been
shown to cause a decrease in insulin gene transcription (21) as
described above, the DNA binding activity to the E element
(IEF1 activity) was not reduced in HIT or bTC6 cells that had
been exposed to chronic high glucose concentrations (7, 28).
Therefore, it still remains obscure whether the E2A/Pan-
dependent suppression of insulin gene transcription can be in-
volved pathophysiologically in the decreased insulin synthesis
in some NIDDM cases. On the other hand, the DNA-binding
activity of another insulin gene transcription factor, RIPE3b1,
also seemed to be suppressed by chronic exposure of HIT (38)
or bTC6 cells (28) to high glucose concentrations. In the case
of bTC6 cells, the binding of PDX-1 was not decreased despite
the reduction of insulin gene promoter activity (28), providing
support for the pathophysiological significance of reduction of
RIPE3b1 activity.
In this study, we used b cell–derived cell lines rather than
primary pancreatic b cells. Although both of the two cell lines
used (MIN6 and bTC1) gave similar results in terms of the ef-
fects of PDX-1 suppression on insulin gene transcription, it is
still possible that normal regulation of the insulin gene is al-
tered in those cell lines. As support for this possibility, Melloul
et al. showed previously that at least some portions of the insu-
lin gene–regulating machinery may be altered in the b cell–
derived cell lines (39). Therefore, similar experiments need to
be performed with primary pancreatic islet cells in order to ob-
tain conclusive evidence for the physiological role of PDX-1 in
vivo.
In conclusion, our observations obtained from antisense
ODN experiments indicate that a moderate decrease in PDX-1
causes no change in the expression of b cell–specific genes
such as the insulin gene. Thus, the amount of PDX-1 per se
does not seem to be relevant to the rate of insulin gene expres-
sion at least as long as it is above a certain level, and it is
unlikely to primarily explain the decrease in insulin gene tran-
scription caused by chronic high glucose exposure. To under-
stand the molecular basis of b cell glucose toxicity, research
needs to be aimed at other components of the insulin gene–
regulating machinery.
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Figure 7. Evaluation of 
PDX-1 and insulin 
mRNA expression in 
HIT-T15 cells chroni-
cally exposed to high 
glucose. Top, Result of 
Western blot analysis 
which used anti–PDX-1 
antiserum and 3 mg of 
nuclear extracts. Middle, 
Result of Northern blot 
analysis which used
10 mg of total RNA and 
a 32P-labeled insulin 
cDNA as a binding 
probe. Nuclear extracts 
and total RNA were 
prepared from HIT-T15 
cells of passages 70 
(P70) and 98 (P98) 
which had been kept
under high glucose con-
dition. Bottom, Ribo-
somal RNA.
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